Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | active not recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04627246 | Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer | active not recruiting | Phase 1 | 14 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | active not recruiting | Phase 2 | 12 | Brandon Huffman, MDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05043857 | Stereotactic PAncreatic RadioTherapy Adjuvant Therapy(SPARTA) | active not recruiting | N/A | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03033927 | Predicting Effective Therapy in Pancreatic Cancer | active not recruiting | — | 74 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04837833 | An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma | active not recruiting | N/A | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05973331 | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | active not recruiting | — | 6,134,060 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT04940286 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04837118 | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | active not recruiting | N/A | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04449406 | Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers(UroPanc) | active not recruiting | — | 3,500 | Queen Mary University of LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04281290 | Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)(PanECT) | active not recruiting | N/A | 10 | University Medical Centre LjubljanaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06712797 | Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center(PANTHER-PIC) | active not recruiting | N/A | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04395469 | FAZA PET/MRI Pancreas | active not recruiting | N/A | 20 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03164486 | First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide | active not recruiting | Early Phase 1 | 27 | Julie L. Sutcliffe, Ph.DOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | active not recruiting | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05927298 | Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial(ProsperPanc) | active not recruiting | — | 200 | University Health Network, TorontoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02336087 | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery | active not recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05634720 | Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | active not recruiting | Phase 4 | 20 | Duke UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05210322 | Percutaneous Cholangiopancreatoscopy Registry | active not recruiting | — | 679 | Johns Hopkins UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05708599 | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | active not recruiting | N/A | 102 | Boehringer IngelheimINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 42 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04684862 | Infusion System for Hepatic Cancer | active not recruiting | N/A | 100 | Ronald DeMatteo, M.D.OTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05921552 | Senior Adult Hepatobiliary Prehab Study | active not recruiting | N/A | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04002479 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer | active not recruiting | N/A | 37 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2026source: clinicaltrials